Uppsala Monitoring Centre
Uppsala Monitoring Centre (UMC) is a global pharmacovigilance centre located in Uppsala, Sweden. It is an independent foundation that works to advance the science of pharmacovigilance and improve patient safety worldwide.
History
The UMC was established in 1978 by the World Health Organization (WHO) as a response to the Thalidomide disaster in the 1960s. The centre was set up to monitor the safety of medicines and to promote rational use of drugs in member countries.
Role and Function
The UMC's primary role is to manage the WHO Programme for International Drug Monitoring, which collects and analyses reports of suspected adverse drug reactions from over 130 member countries. The centre maintains the largest database of its kind in the world, known as VigiBase, which contains over 20 million reports of suspected adverse drug reactions.
The UMC also provides training and support to national pharmacovigilance centres, conducts research into drug safety, and develops tools and guidelines to support pharmacovigilance activities worldwide.
VigiBase
VigiBase is the global database for individual case safety reports (ICSRs), managed by the UMC. It is the largest database of its kind, containing reports from over 130 countries. The database is used to detect signals of potential safety issues with medicines, which can then be investigated further.
Signal Detection
One of the key functions of the UMC is signal detection. This involves analysing data from VigiBase to identify new or changing safety issues with medicines. The UMC uses a range of statistical methods and algorithms to detect signals, and publishes its findings in the WHO Pharmaceuticals Newsletter.
Training and Support
The UMC provides training and support to national pharmacovigilance centres around the world. This includes training in signal detection, data management, and the use of VigiBase. The centre also develops tools and guidelines to support pharmacovigilance activities.
Research
The UMC conducts research into drug safety and pharmacovigilance. This includes studies into the causes and prevention of adverse drug reactions, the effectiveness of pharmacovigilance systems, and the use of real-world data in drug safety research.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
